Advertisement

An Analysis of Class I Recalls: 1982–1996

Abstract

Class I recalls possess the greatest degree of health hazard and are frequently conducted to the consumer or user level. This study analyzes all Class I recalls appearing in the Food and Drug Administration (FDA) Enforcement Reports from 1982–1996. Major causes of Class I recalls over the past 14 years include: drug quality and good manufacturing practices (GMP) violations, mislabeling, and adverse reactions. Class 1 recalls over this time period are analyzed by reason, brand versus generic company, dosage form (eg, injection, tablet), notification method, and further FDA enforcement action (eg, seizure, injunction, criminal prosecution). Trends are identified. Finally, the effectiveness of Class I recalls to the pharmacy level is assessed.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    43 Federal Register 26202 (1978).

  2. 2.

    Fine SD. Recalls—Definition and exposition. Food Drug Cosmetic Law J. 1972;27:662–671.

  3. 3.

    Harper BM. Mandatory food and drug recalls. An analysis of a developing FDA enforcement tool. Food Drug Cosmetic Law J. 1981;35:669–687.

  4. 4.

    Rumore MM. The drug product recall system and the pharmacist: Are consumers protected? N. Y. State J. Health Syst Pharm. 1996;15(10):137–159.

  5. 5.

    FDA Enforcement Manual. Tab 600. Recalls and administrative injunction. Thompson Publications Group, Inc.; 1992:44.

  6. 6.

    FDA Regulatory Procedures Manual. Part 5, Ch. 5.00-20. Recall and emergency procedures.

  7. 7.

    Clevenger WL. Recalls. Food, Drug, Cosmetic Law J. 1972;27:332–343.

  8. 8.

    Parker BR, Valentino G. Handling a pharmaceutical recall: why it pays to do it right. Drug lnf J. 1994; 28:899–813.

  9. 9.

    Labeling/packaging error recalls down 43% in 1996. The Pink Sheet. T&G 6–7, January 20, 1997.

  10. 10.

    FDA seeks labeling regulation changes, disclosure of clinical trials in preliminary legislative agenda. FDC Reports—The Pink Sheet. 59(11):3–4, March 17, 1997.

  11. 11.

    Gumbhir AK, Jamison ML. Assessing the effectiveness of drug recalls in pharmacies. Drug & Cosmetic Ind. 1975;117:40–43, 113.

  12. 12.

    U.S.P. Quality Review. The U.S.P. Convention. 8/96.

Download references

Author information

Correspondence to Martha M. Rumore PharmD, JD, RAC, FAPhA.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rumore, M.M. An Analysis of Class I Recalls: 1982–1996. Ther Innov Regul Sci 32, 65–71 (1998) doi:10.1177/009286159803200109

Download citation

Key Words

  • Class I recalls
  • Mislabeling
  • Brand versus generic
  • Dosage form
  • Recall notification